Trial Profile
Phase II Multi-Centre, Randomized, Parallel Group, Pilot Trial to Compare the Incidence of Tocilizumab Related Infusion Reactions in Moderate to Severe RA Patients When Infusion is Made Over 1 Hour Against 31 Minutes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Roche
- 04 May 2012 Status changed from active, no longer recruiting to completed, according to the European Clinical Trials Database.
- 18 May 2011 Planned end date changed from 1 Dec 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
- 18 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.